Research presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA, adds support for use of pembrolizumab plus axitinib as a first-line treatment for patients with metastatic renal cell carcinoma.
Lurbinectedin monotherapy is active in the second-line treatment of both platinum-sensitive and -resistant small-cell lung cancer, according to phase II results presented at the 2019 ASCO Annual Meeting.
Preliminary findings for a first-in-human study of JNJ-372 – a bispecific IgG antibody targeting both the EGFR and cMET receptors – have been reported at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.
Preliminary results from a pivotal trial of enfortumab vedotin, an antibody–drug conjugate targeting Nectin-4, show a “clinically meaningful” response in patients with unresectable locally advanced or metastatic urothelial cancer.
The degree of response to olaparib among patients with heavily pretreated metastatic castration-resistant prostate cancer varies according to the type of DNA damage repair alteration the tumor carries, research shows.
Early results suggest that a novel antibody–drug conjugate directed against HER3 has antitumor activity and manageable safety in patients with EGFR-mutated metastatic non-small-cell lung cancer and acquired resistance to EGFR–tyrosine kinase inhibitors.
Supplementing androgen deprivation therapy with apalutamide leads to significant improvements in survival outcomes in men with metastatic castration-sensitive prostate cancer, show phase III trial results.
Individuals with urothelial cancer who respond to treatment with PD-1 or PD-L1 inhibitors are more likely to report adverse events of special interest, including immune-mediated events, than nonresponders, results of a pooled analysis show.
Patients with treatment-naïve, nonmutated, nonsquamous, advanced non-small-cell lung cancer derive a significant survival benefit from the addition of the PD-L1 inhibitor atezolizumab to chemotherapy, indicate phase III trial findings.
Research published in JAMA Oncology confirms that prostate cancer-specific mortality is not significantly different between Black and White men with nonmetastatic disease when access to care and treatment is comparable.
Marginal survival gains among patients with small-cell lung cancer who receive twice- versus once-daily thoracic radiotherapy plus prophylactic cranial irradiation occur at the cost of an increased risk for brain metastases, research shows.
Extended follow-up of patients with unresectable locally advanced or metastatic urothelial carcinoma in the CheckMate 032 trial shows sustained antitumor activity of nivolumab alone and in combination with ipilimumab.
Adding nintedanib to pemetrexed plus cisplatin does not improve progression-free survival for patients with advanced malignant pleural mesothelioma, say researchers who conducted a phase III trial on the basis of earlier positive findings.
The circulating tumor cell count can identify patients with limited-stage small-cell lung cancer who are likely to have poor survival outcomes despite treatment, report researchers who have identified 15 cells per 7.5 mL as the optimal cutoff.